MedTrace Logo

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

NCT01386723 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2018-07-17

No results posted yet for this study

Summary

This study proposes to observe whether a stable platelet count would be maintained without additional treatment in the long term in at least a proportion of patients who have discontinued eltrombopag taken for at least 4 months. This requires that if patients stop treatment with eltrombopag, they are not immediately transitioned to further treatment unless it is necessary.

The objective of the study is to assess how frequently patients who have discontinued eltrombopag attain a stable, treatment-free, unmaintained adequate platelet count 4 to 8 weeks after discontinuing eltrombopag and how long such a response lasts (if it occurs).

Conditions

Interventions

DRUG

Discontinuation of eltrombopag

Observation of subjects as they discontinue the use of eltrombopag

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • James B. Bussel, M.D. · Weill Medical College of Cornell University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2017-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01386723 on ClinicalTrials.gov